NSCLC生物标志物检测，预测免疫疗法应答的生物标志物(2)
病例: 转移性非鳞NSCLC的治疗
If PD-L1 ≥50% - Single-agent immune checkpoint inhibitor - Carboplatin/taxane/pembrolizumab If PD-L1 <50% - Carboplatin/taxane/pembrolizumab - Molecular testing may identify actionable drivers Role of TMB remains less clear
【相关文章】
赞 (0)